U.S. markets close in 4 hours 32 minutes
  • S&P 500

    3,810.05
    +59.28 (+1.58%)
     
  • Dow 30

    30,844.05
    +540.88 (+1.78%)
     
  • Nasdaq

    13,384.58
    +113.98 (+0.86%)
     
  • Russell 2000

    2,113.44
    +4.74 (+0.22%)
     
  • Crude Oil

    52.66
    -0.19 (-0.36%)
     
  • Gold

    1,859.10
    +10.20 (+0.55%)
     
  • Silver

    26.69
    +1.30 (+5.12%)
     
  • EUR/USD

    1.2130
    +0.0019 (+0.16%)
     
  • 10-Yr Bond

    1.0450
    +0.0310 (+3.06%)
     
  • GBP/USD

    1.3728
    +0.0036 (+0.26%)
     
  • USD/JPY

    104.3190
    +0.2470 (+0.24%)
     
  • BTC-USD

    31,937.17
    +2,109.26 (+7.07%)
     
  • CMC Crypto 200

    645.98
    +18.31 (+2.92%)
     
  • FTSE 100

    6,531.95
    -35.42 (-0.54%)
     
  • Nikkei 225

    28,197.42
    -437.79 (-1.53%)
     

Cerus Corporation to Participate in Upcoming Virtual Investor Conferences

·2 min read

Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in two conferences:

  • The Stifel Virtual Healthcare Conference on Monday, November 16th at 1:20 P.M. ET.

  • The Stephens Annual Investment Conference on Thursday, November 19th at 3:00 P.M. ET.

A live webcast of the events will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Based in Concord, California, our employees are dedicated to deploying and supplying vital technologies and pathogen-protected blood components for blood centers, hospitals and ultimately patients who rely on safe blood. With the INTERCEPT Blood System, we are focused on protecting patients by delivering the full complement of reliable products and expertise for transfusion medicine. Cerus develops and markets the INTERCEPT Blood System and remains the only company in the blood transfusion space to earn both CE Mark and FDA approval for pathogen reduction of both platelet and plasma components. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005409/en/

Contacts

Jessica Hanover – VP, Corporate Affairs
Cerus Corporation
925-288-6137